EcoDrugPlus

Nitric Oxide Synthase 2

Ensembl ID : ENSPTIG00000013237
Gene Symbol: NOS2
2 Cross references
163 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSPTIG00000007860
Gene Symbol: NOTCH3
2 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSPTIG00000013951
Gene Symbol: NFKB1
2 Cross references
200 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSPTIG00000017281
Gene Symbol: NR1H2
2 Cross references
305 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSPTIG00000018538
Gene Symbol: NR1H3
2 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSPTIG00000016103
Gene Symbol: NR1H4
2 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSPTIG00000000485
Gene Symbol: NR3C1
2 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSPTIG00000017479
Gene Symbol: NR3C2
2 Cross references
212 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSPTIG00000007371
Gene Symbol: NOD2
2 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSPTIG00000012209
Gene Symbol: OPRD1
1 Cross references
252 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSPTIG00000010696
Gene Symbol: OPRK1
2 Cross references
262 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSPTIG00000006702
Gene Symbol: OPRM1
2 Cross references
214 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).